Saunders M I, Dische S, Kogelnik H D, Sealy R, Lenox-Smith I
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):263-8.
Misonidazole, a 2-nitroimidazole, is receiving extensive trial as a radiosensitizing drug in the treatment of patients with malignant disease. Drug sensitivity rashes have been observed and the collected cases from three centers are reported. Of a total of 380 patients there were five (1.3%) instances of definite rash and ten (2.6%) instances of observed rash. These figures are compared with the incidence of sensitivity rashes with other drugs in the nitroimidazole group.
米索硝唑，一种2-硝基咪唑，作为一种放射增敏药物在恶性疾病患者的治疗中正在接受广泛试验。已观察到药物敏感性皮疹，并报告了来自三个中心收集的病例。在总共380名患者中，有5例（1.3%）出现明确皮疹，10例（2.6%）出现观察到的皮疹。这些数字与硝基咪唑类组中其他药物的敏感性皮疹发生率进行了比较。
